Peter Ordentlich
Fondateur chez SYNDAX PHARMACEUTICALS, INC.
Fortune : 5 451 $ au 30/04/2024
Postes actifs de Peter Ordentlich
Sociétés | Poste | Début | Fin |
---|---|---|---|
SYNDAX PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/11/2013 | - |
Fondateur | 11/10/2005 | - |
Historique de carrière de Peter Ordentlich
Anciens postes connus de Peter Ordentlich
Sociétés | Poste | Début | Fin |
---|---|---|---|
X-Ceptor Therapeutics, Inc.
X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Corporate Officer/Principal | - | - |
The Salk Institute for Biological Studies | Corporate Officer/Principal | - | - |
Formation de Peter Ordentlich
University of Pennsylvania | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 5 |
Opérationnelle
Corporate Officer/Principal | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Sectorielle
Consumer Services | 3 |
Health Technology | 2 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
SYNDAX PHARMACEUTICALS, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
X-Ceptor Therapeutics, Inc.
X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Commercial Services |
- Bourse
- Insiders
- Peter Ordentlich
- Expérience